Related references
Note: Only part of the references are listed.The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy A retrospective analysis
Kevin M. Pantalone et al.
DIABETES CARE (2010)
Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction
Marianne Zeller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
Kevin M. Pantalone et al.
ACTA DIABETOLOGICA (2009)
Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Mykola Khalangot et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study
Henriette T. Horsdal et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2009)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis
Josie M. M. Evans et al.
DIABETES OBESITY & METABOLISM (2008)
Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease
Matteo Monami et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Sonia Correia et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2008)
Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration
Kristijan H. Kahler et al.
DIABETES CARE (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin
Matteo Monami et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2006)
Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example
Geert J. M. G. van der Heijden et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits
DM Flynn et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study
M Gulliford et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
Sulphonylurea action revisited - the post-cloning era
FM Gribble et al.
DIABETOLOGIA (2003)
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
JA Johnson et al.
DIABETES CARE (2002)
Glimepiride block of cloned ß-cell, cardiac and smooth muscle KATP channels
DK Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
The abuse of power: The pervasive fallacy of power calculations for data analysis
JM Hoenig et al.
AMERICAN STATISTICIAN (2001)
Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up
EZ Fisman et al.
CLINICAL CARDIOLOGY (2001)
Increased mortality in Type I diabetic patients using sulphonylurea and metformin in combination:: a population-based observational study
J Olsson et al.
DIABETOLOGIA (2000)
Share Paper
